AI Center 用户指南

Japan NNP B-NP B-LOC
began VBD B-VP O
the DT B-NP O
defence NN I-NP O
of IN B-PP O
their PRP$ B-NP O
Asian JJ I-NP B-MISC
Cup NNP I-NP I-MISC
title NN I-NP O
with IN B-PP O
a DT B-NP O
lucky JJ I-NP O
2-1 CD I-NP O
win VBP B-VP O
against IN B-PP O
Syria NNP B-NP B-LOC
in IN B-PP O
a DT B-NP O
Group NNP I-NP O
C NNP I-NP O
championship NN I-NP O
match NN I-NP O
on IN B-PP O
Friday NNP B-NP O
. . O OFounding O
member O
Kojima B-PER
Minoru I-PER
played O
guitar O
on O
Good B-MISC
Day I-MISC
, O
and O
Wardanceis I-MISC
cover O
of O
a O
song O
by O
UK I-LOC
post O
punk O
industrial O
band O
Killing B-ORG
Joke I-ORG
. OJapan NNP B-NP B-LOC
began VBD B-VP O
the DT B-NP O
defence NN I-NP O
of IN B-PP O
their PRP$ B-NP O
Asian JJ I-NP B-MISC
Cup NNP I-NP I-MISC
title NN I-NP O
with IN B-PP O
a DT B-NP O
lucky JJ I-NP O
2-1 CD I-NP O
win VBP B-VP O
against IN B-PP O
Syria NNP B-NP B-LOC
in IN B-PP O
a DT B-NP O
Group NNP I-NP O
C NNP I-NP O
championship NN I-NP O
match NN I-NP O
on IN B-PP O
Friday NNP B-NP O
. . O OFounding O
member O
Kojima B-PER
Minoru I-PER
played O
guitar O
on O
Good B-MISC
Day I-MISC
, O
and O
Wardanceis I-MISC
cover O
of O
a O
song O
by O
UK I-LOC
post O
punk O
industrial O
band O
Killing B-ORG
Joke I-ORG
. O

{
    "text": "Serotonin receptor 2A ( HTR2A ) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder . anxiety disorder ( GAD ) is a chronic psychiatric disorder with significant morbidity and mortality .\)
Antidepressant drugs are the preferred choice for treatment ; however , treatment response is often variable .\)
Several studies in major depression have implicated a role of the serotonin receptor gene ( HTR2A ) in treatment response to antidepressants .\)
We tested the hypothesis that the genetic polymorphism rs7997012 in the HTR2A gene predicts treatment outcome in GAD patients treated with venlafaxine XR . Treatment response was assessed in 156 patients that participated in a 6-month open - label clinical trial of venlafaxine XR for GAD . Primary analysis included Hamilton Anxiety Scale ( HAM-A ) reduction at 6 months .\)
Secondary outcome measure was the Clinical Global Impression of Improvement ( CGI-I ) score at 6 months .\)
Genotype and allele frequencies were compared between groups using χ(2) contingency analysis .\)
The frequency of the G-allele differed significantly between responders ( 70% ) and nonresponders ( 56% ) at 6 months ( P=0.05 ) using the HAM-A scale as outcome measure .\)
Similarly , using the CGI-I as outcome , the G-allele was significantly associated with improvement ( P=0.01 ) .\)
Assuming a dominant effect of the G-allele , improvement differed significantly between groups ( P=0.001 , odds ratio=4.72 ) .\)
Similar trends were observed for remission although not statistically significant .\)
We show for the first time a pharmacogenetic effect of the HTR2A rs7997012 variant in anxiety disorders , suggesting that pharmacogenetic effects cross diagnostic categories .\)
Our data document that individuals with the HTR2A rs7997012 single nucleotide polymorphism G-allele have better treatment outcome over time .\)
Future studies with larger sample sizes are necessary to further characterize this effect in treatment response to antidepressants in GAD .",
    "entities": [{
        "entity": "TRIVIAL",
        "value": "Serotonin",
        "start_index": 0,
        "end_index": 9
    }, {
        "entity": "TRIVIAL",
        "value": "venlafaxine",
        "start_index": 81,
        "end_index": 92
    }, {
        "entity": "TRIVIAL",
        "value": "serotonin",
        "start_index": 409,
        "end_index": 418
    }, {
        "entity": "TRIVIAL",
        "value": "venlafaxine",
        "start_index": 625,
        "end_index": 636
    }, {
        "entity": "TRIVIAL",
        "value": "venlafaxine",
        "start_index": 752,
        "end_index": 763
    }, {
        "entity": "FAMILY",
        "value": "nucleotide",
        "start_index": 1800,
        "end_index": 1810
    }]
}{
    "text": "Serotonin receptor 2A ( HTR2A ) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder . anxiety disorder ( GAD ) is a chronic psychiatric disorder with significant morbidity and mortality .\)
Antidepressant drugs are the preferred choice for treatment ; however , treatment response is often variable .\)
Several studies in major depression have implicated a role of the serotonin receptor gene ( HTR2A ) in treatment response to antidepressants .\)
We tested the hypothesis that the genetic polymorphism rs7997012 in the HTR2A gene predicts treatment outcome in GAD patients treated with venlafaxine XR . Treatment response was assessed in 156 patients that participated in a 6-month open - label clinical trial of venlafaxine XR for GAD . Primary analysis included Hamilton Anxiety Scale ( HAM-A ) reduction at 6 months .\)
Secondary outcome measure was the Clinical Global Impression of Improvement ( CGI-I ) score at 6 months .\)
Genotype and allele frequencies were compared between groups using χ(2) contingency analysis .\)
The frequency of the G-allele differed significantly between responders ( 70% ) and nonresponders ( 56% ) at 6 months ( P=0.05 ) using the HAM-A scale as outcome measure .\)
Similarly , using the CGI-I as outcome , the G-allele was significantly associated with improvement ( P=0.01 ) .\)
Assuming a dominant effect of the G-allele , improvement differed significantly between groups ( P=0.001 , odds ratio=4.72 ) .\)
Similar trends were observed for remission although not statistically significant .\)
We show for the first time a pharmacogenetic effect of the HTR2A rs7997012 variant in anxiety disorders , suggesting that pharmacogenetic effects cross diagnostic categories .\)
Our data document that individuals with the HTR2A rs7997012 single nucleotide polymorphism G-allele have better treatment outcome over time .\)
Future studies with larger sample sizes are necessary to further characterize this effect in treatment response to antidepressants in GAD .",
    "entities": [{
        "entity": "TRIVIAL",
        "value": "Serotonin",
        "start_index": 0,
        "end_index": 9
    }, {
        "entity": "TRIVIAL",
        "value": "venlafaxine",
        "start_index": 81,
        "end_index": 92
    }, {
        "entity": "TRIVIAL",
        "value": "serotonin",
        "start_index": 409,
        "end_index": 418
    }, {
        "entity": "TRIVIAL",
        "value": "venlafaxine",
        "start_index": 625,
        "end_index": 636
    }, {
        "entity": "TRIVIAL",
        "value": "venlafaxine",
        "start_index": 752,
        "end_index": 763
    }, {
        "entity": "FAMILY",
        "value": "nucleotide",
        "start_index": 1800,
        "end_index": 1810
    }]
}

{
    "annotations": {
        "intent": {
            "to_name": "text",
            "choices": [
                "TransactionIssue",
                "LoanIssue"
            ]
        },
        "sentiment": {
            "to_name": "text",
            "choices": [
                "Very Positive"
            ]
        },
        "ner": {
            "to_name": "text",
            "labels": [
                {
                    "start_index": 37,
                    "end_index": 47,
                    "entity": "Stakeholder",
                    "value": " Citi Bank"
                },
                {
                    "start_index": 51,
                    "end_index": 61,
                    "entity": "Date",
                    "value": "07/19/2018"
                },
                {
                    "start_index": 114,
                    "end_index": 118,
                    "entity": "Amount",
                    "value": "$500"
                },
                {
                    "start_index": 288,
                    "end_index": 293,
                    "entity": "Stakeholder",
                    "value": " Citi"
                }
            ]
        }
    },
    "data": {
        "cc": "",
        "to": "[email protected]",
        "date": "1/29/2020 12:39:01 PM",
        "from": "[email protected]",
        "text": "I opened my new checking account with Citi Bank in 07/19/2018 and met the requirements for the promotion offer of $500 . It has been more than 6 months and I have not received any bonus. I called the customer service several times in the past few months but no any response. I request the Citi honor its promotion offer as advertised."{
    "annotations": {
        "intent": {
            "to_name": "text",
            "choices": [
                "TransactionIssue",
                "LoanIssue"
            ]
        },
        "sentiment": {
            "to_name": "text",
            "choices": [
                "Very Positive"
            ]
        },
        "ner": {
            "to_name": "text",
            "labels": [
                {
                    "start_index": 37,
                    "end_index": 47,
                    "entity": "Stakeholder",
                    "value": " Citi Bank"
                },
                {
                    "start_index": 51,
                    "end_index": 61,
                    "entity": "Date",
                    "value": "07/19/2018"
                },
                {
                    "start_index": 114,
                    "end_index": 118,
                    "entity": "Amount",
                    "value": "$500"
                },
                {
                    "start_index": 288,
                    "end_index": 293,
                    "entity": "Stakeholder",
                    "value": " Citi"
                }
            ]
        }
    },
    "data": {
        "cc": "",
        "to": "[email protected]",
        "date": "1/29/2020 12:39:01 PM",
        "from": "[email protected]",
        "text": "I opened my new checking account with Citi Bank in 07/19/2018 and met the requirements for the promotion offer of $500 . It has been more than 6 months and I have not received any bonus. I called the customer service several times in the past few months but no any response. I request the Citi honor its promotion offer as advertised."